Vanda Pharmaceuticals Inc
VNDA
Get informed when a big investor buys or sells
+ FollowMarket Cap$375.25M
Close$
$-3.75
164.1% downside
Current Fair Value
164.1% downsideOvervalued by 164.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $375.25 Million |
|---|---|
| Enterprise Value | $328.26 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.74 |
| Beta | 0.6 |
| Outstanding Shares | 59,459,982 |
Return
| Return on Equity | -85.32% |
|---|---|
| Return on Assets | -55.26% |
| Return on Invested Capital | -52.85% |
Valuation & Multiples
| P/E Ratio | -1.54 |
|---|---|
| PEG | -2.38 |
| Price to Sales | 1.95 |
| Price to Book Ratio | 1.46 |
| Enterprise Value to Revenue | 1.51 |
| Enterprise Value to EBIT | -2.08 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 6, 2026
EPS Estimate
$-0.53
Average shareholder expectationRevenue Estimate
$54.98 M
Average shareholder expectationNext Earnings Call
Expected Date
July 30, 2026
EPS Estimate
$-0.58
Average shareholder expectationRevenue Estimate
$61.92 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 28.18% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.01%▼ 78.18% |
|---|---|
| Total Invested | $47,167▼ 99.99% |
| Investors Holding | 3▼ 171.00% |
ESG Score
No data
About Vanda Pharmaceuticals Inc
CEO: Mihael Polymeropoulos Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.